NCT03150056 2022-08-10Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate CancerGlaxoSmithKlinePhase 1 Terminated73 enrolled 34 charts
NCT02056392 2015-11-09To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male VolunteersAstraZenecaPhase 1 Completed54 enrolled 31 charts